1. Home
  2. SMMT
  3. SMMT News

Latest Summit Therapeutics Inc. (SMMT) News on October 18, 2024

Up 700% This Year, Is It Too Late to Invest in This Stock?
SMMT

Motley Fool

3 days ago

Up 700% This Year, Is It Too Late to Invest in This Stock?

Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
SMMT

Motley Fool

4 days ago

Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics

3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
SMMT

Motley Fool

6 days ago

3 Things You Need to Know If You Buy Summit Therapeutics Stock Today

Summit Therapeutics Inc (SMMT) Q2 2024 Earnings Call Highlights: Strategic Advances and ...
SMMT

GuruFocus.com

8 days ago

Summit Therapeutics Inc (SMMT) Q2 2024 Earnings Call Highlights: Strategic Advances and ...

2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
SMMT

Motley Fool

11 days ago

2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts

Summit Therapeutics Inc. (SMMT): Hedge Funds Are Bullish On This NASDAQ Stock Right Now
SMMT

Insider Monkey

12 days ago

Summit Therapeutics Inc. (SMMT): Hedge Funds Are Bullish On This NASDAQ Stock Right Now

Is Summit Therapeutics a Millionaire Maker?
SMMT

Motley Fool

12 days ago

Is Summit Therapeutics a Millionaire Maker?

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SMMT

Business Wire

13 days ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track
SMMT

Investopedia

14 days ago

Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track

SMMT

MT Newswires

14 days ago

Sector Update: Health Care Stocks Rise Pre-Bell Friday

SMMT

MT Newswires

14 days ago

Sector Update: Health Care

Could Summit Therapeutics Become the Next Merck?
SMMT

Motley Fool

14 days ago

Could Summit Therapeutics Become the Next Merck?

Is Summit Therapeutics Inc. (SMMT) the Best High Short Interest Stock to Invest In Now?
SMMT

Insider Monkey

14 days ago

Is Summit Therapeutics Inc. (SMMT) the Best High Short Interest Stock to Invest In Now?

SMMT

MT Newswires

14 days ago

Update: Summit Therapeutics Closes Phase 3 Lung Cancer Study Enrollment, Gets FDA Fast Track; Shares up Premarket

Summit completes subject enrolment in Phase III NSCLC treatment trial
SMMT

Clinical Trials Arena

14 days ago

Summit completes subject enrolment in Phase III NSCLC treatment trial

SMMT

MT Newswires

14 days ago

Summit Therapeutics Completes Enrollment in Phase 3 Lung Cancer Drug Study

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
SMMT

Business Wire

14 days ago

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Where Will Summit Therapeutics Be in 3 Years?
SMMT

Motley Fool

15 days ago

Where Will Summit Therapeutics Be in 3 Years?

Has Summit Therapeutics Stock Already Peaked?
SMMT

Motley Fool

16 days ago

Has Summit Therapeutics Stock Already Peaked?

Is Summit Therapeutics Stock a Buy?
SMMT

Motley Fool

18 days ago

Is Summit Therapeutics Stock a Buy?

2 High-Potential Growth Stocks You Shouldn't Overlook
SMMT

Motley Fool

19 days ago

2 High-Potential Growth Stocks You Shouldn't Overlook

Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
SMMT

Motley Fool

20 days ago

Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics

Is Summit Therapeutics Inc. (SMMT) the Best Performing Stock in 2024?
SMMT

Insider Monkey

22 days ago

Is Summit Therapeutics Inc. (SMMT) the Best Performing Stock in 2024?

2 Stocks Up Over 700% in 2024 That Could Soar Even Further
SMMT

Motley Fool

23 days ago

2 Stocks Up Over 700% in 2024 That Could Soar Even Further

How a Surfer Who Never Finished College Became a Biotech Billionaire
SMMT

The Wall Street Journal

25 days ago

How a Surfer Who Never Finished College Became a Biotech Billionaire

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
SMMT

Motley Fool

25 days ago

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?

SMMT

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise Premarket Friday

Keytruda beaten by Summit’s bispecific in NSCLC
SMMT

Clinical Trials Arena

a month ago

Keytruda beaten by Summit’s bispecific in NSCLC

SMMT

MT Newswires

a month ago

Summit Therapeutics Registers for Secondary Offering of 10.4 Million Shares

BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.
SMMT

Barrons.com

a month ago

BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.

Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
SMMT

Motley Fool

a month ago

Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?

This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
SMMT

Motley Fool

a month ago

This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.

How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery
SMMT

Investor's Business Daily

a month ago

How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery

Here's Why Everyone's Talking About Summit Therapeutics
SMMT

Motley Fool

a month ago

Here's Why Everyone's Talking About Summit Therapeutics

Instil Bio Stock Skyrockets 641% in One Week: Here's Why
SMMT

Zacks

a month ago

Instil Bio Stock Skyrockets 641% in One Week: Here's Why

SMMT

MT Newswires

a month ago

Summit Therapeutics Reports High Response Rates from Ivonescimab Trials in Cancer Studies

Insider Buying: Summit Therapeutics Co-CEO & Executive Chairman Bought US$75m Of Shares
SMMT

Simply Wall St.

a month ago

Insider Buying: Summit Therapeutics Co-CEO & Executive Chairman Bought US$75m Of Shares

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
SMMT

Business Wire

a month ago

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

Is Summit Therapeutics Inc. (NASDAQ:SMMT) an Unstoppable Growth Stock To Buy Now?
SMMT

Insider Monkey

a month ago

Is Summit Therapeutics Inc. (NASDAQ:SMMT) an Unstoppable Growth Stock To Buy Now?

Why Summit Therapeutics Skyrocketed 123% This Week
SMMT

Motley Fool

a month ago

Why Summit Therapeutics Skyrocketed 123% This Week

Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
SMMT

Investor's Business Daily

a month ago

Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale

SMMT

MT Newswires

a month ago

Sector Update: Health Care Stocks Edge Higher in Afternoon Trading

Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
SMMT

Zacks

a month ago

Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More

Why Summit Therapeutics Stock Is Soaring Again Today
SMMT

Motley Fool

a month ago

Why Summit Therapeutics Stock Is Soaring Again Today

SMMT

MT Newswires

a month ago

Update: Summit Therapeutics Shares Jump After Company Raises $235 Million

SMMT

MT Newswires

a month ago

Summit Therapeutics Raises $235 Million from Insiders, Institutional Investors

Summit Therapeutics Raises $235 Million
SMMT

Business Wire

a month ago

Summit Therapeutics Raises $235 Million

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
SMMT

Zacks

a month ago

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda

MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
SMMT

Zacks

a month ago

MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study

Company News for Sep 10, 2024
SMMT

Zacks

a month ago

Company News for Sep 10, 2024

Is Summit Therapeutics a Buy Now?
SMMT

Motley Fool

a month ago

Is Summit Therapeutics a Buy Now?

Merck Dives After Summit — Up 56% — Sneaks In With Keytruda-Walloping Punch
SMMT

Investor's Business Daily

a month ago

Merck Dives After Summit — Up 56% — Sneaks In With Keytruda-Walloping Punch

Why Summit Therapeutics Rocketed Over 60% Today
SMMT

Motley Fool

a month ago

Why Summit Therapeutics Rocketed Over 60% Today

SMMT

MT Newswires

a month ago

Top Midday Gainers

A Better Drug Than Merck’s Blockbuster Keytruda? Not So Fast
SMMT

The Wall Street Journal

a month ago

A Better Drug Than Merck’s Blockbuster Keytruda? Not So Fast

SMMT

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise Monday Afternoon

Summit’s checkpoint inhibitor trumps Keytruda in lung cancer trial
SMMT

Pharmaceutical Technology

a month ago

Summit’s checkpoint inhibitor trumps Keytruda in lung cancer trial

SMMT

MT Newswires

a month ago

Update: Summit Therapeutics' Trial Shows Ivonescimab Significantly Improved Progression-Free Survival, Shares Rise

Merck stock falls on Summit cancer drug's trial results
SMMT

Yahoo Finance Video

a month ago

Merck stock falls on Summit cancer drug's trial results

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
SMMT

Business Wire

a month ago

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China

Summit lung cancer drug shows ‘striking’ benefit over Keytruda
SMMT

BioPharma Dive

a month ago

Summit lung cancer drug shows ‘striking’ benefit over Keytruda

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SMMT

Business Wire

a month ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Insiders Added US$5.84m Of Stock To Their Holdings
SMMT

Simply Wall St.

2 months ago

Summit Therapeutics Insiders Added US$5.84m Of Stock To Their Holdings

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
SMMT

Business Wire

2 months ago

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024
SMMT

PR Newswire

2 months ago

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SMMT

Business Wire

2 months ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SMMT

MT Newswires

2 months ago

Summit Therapeutics' Q2 Non-GAAP Net Loss Widens

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
SMMT

Business Wire

2 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024

Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
SMMT

Business Wire

3 months ago

Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024

Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
SMMT

Business Wire

3 months ago

Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SMMT

Business Wire

3 months ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
SMMT

Business Wire

4 months ago

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
SMMT

Motley Fool

4 months ago

3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street

Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
SMMT

Zacks

4 months ago

Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why

SMMT

MT Newswires

4 months ago

Summit Therapeutics Generates $200 Million Through Share Sale; Expand License Territories for Ivonescimab

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
SMMT

Business Wire

4 months ago

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
SMMT

Business Wire

5 months ago

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
SMMT

Business Wire

5 months ago

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
SMMT

Benzinga

5 months ago

Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study

Summit reports data from Phase III NSCLC treatment trial
SMMT

Clinical Trials Arena

5 months ago

Summit reports data from Phase III NSCLC treatment trial

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SMMT

Business Wire

5 months ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Shares Soar After Cancer Drug Tops Merck’s Keytruda
SMMT

Bloomberg

5 months ago

Summit Shares Soar After Cancer Drug Tops Merck’s Keytruda

SMMT

MT Newswires

5 months ago

Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar

Competitor to Merck's Keytruda Worries Some Investors
SMMT

Barrons.com

5 months ago

Competitor to Merck's Keytruda Worries Some Investors

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
SMMT

Business Wire

5 months ago

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China

Why Summit Therapeutics Stock Is Sinking Today
SMMT

Motley Fool

5 months ago

Why Summit Therapeutics Stock Is Sinking Today

SMMT

MT Newswires

5 months ago

Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced

SMMT

MT Newswires

5 months ago

Top Premarket Decliners

Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript
SMMT

Insider Monkey

6 months ago

Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript

SMMT

GuruFocus.com

6 months ago

Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...

SMMT

Thomson Reuters StreetEvents

6 months ago

Q1 2024 Summit Therapeutics Inc Earnings Call

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
SMMT

Business Wire

6 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
SMMT

Business Wire

6 months ago

Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
SMMT

Business Wire

6 months ago

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
SMMT

Business Wire

6 months ago

Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum

SMMT

Reuters

6 months ago

CORRECTED-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra named successor

Insiders Are Buying These 11 Penny Stocks
SMMT

Insider Monkey

6 months ago

Insiders Are Buying These 11 Penny Stocks

Why Summit Therapeutics Stock Crushed the Market This Week
SMMT

Motley Fool

7 months ago

Why Summit Therapeutics Stock Crushed the Market This Week

Summit Therapeutics Insiders Up US$5.1m On US$5.05m Investment
SMMT

Simply Wall St.

7 months ago

Summit Therapeutics Insiders Up US$5.1m On US$5.05m Investment

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
SMMT

Business Wire

7 months ago

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Share on Social Networks: